Derma Sciences Fund Company Profile

Description

Derma Sciences, Inc. operates as a medical device company in the wound care market. Its Advanced Wound Care segment offers MEDIHONEY dressings for managing non-chronic and hard-to-heal wounds, including chronic ulcers, burns, and post-operative wounds; TCC-EZ system for patients with diabetic foot ulcers; AMNIOEXCEL for tissue repair, reconstruction, and replacement; and AMNIOMATRIX that is used as a wound covering in the treatment of localized tissue defects. This segment also provides XTRASORB dressings, which convert fluid within the dressings to a gel and lock the exudates into the dressings; BIOGUARD dressings for prophylactic use in the prevention of hospital or community acquired infections through wound sites; ALGICELL AG antimicrobial dressings; and occlusive dressings, such as hydrocolloids, foams, hydrogels, alginates, additional silver antimicrobial dressings, cleansers, and DERMAGRAN products. The company’s Traditional Wound Care segment offers gauze sponges and bandages, non-adherent impregnated dressings, retention devices, paste bandages, and other compression devices; adhesive bandages and related first aid products; private-label wound care products; wound closure strips, nasal tube fasteners, and catheter fasteners; and general purpose and specialized skin care products. Derma Sciences, Inc. markets its products to acute care, extended care, home health care, nursing homes, hospitals, wound and burn care clinics and physician offices through direct sales force, independent distributors, and manufacturers’ representatives. The company was founded in 1984 and is headquartered in Princeton, New Jersey.